Complex Event Analysis - Report

Complex Event Analysis - REPORT

Supporting narratives:

• challenge (Read more)
• The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.
  The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv
• High Level Abstractions:
• (microgram,vaccine)

• challenge (Read more)
• Most patients reported pain at the injection site, which was mild to moderate, the company said, except in one of 12 subjects who received a 100 microgram dose, which was severe.
  The findings posted Wednesday have not been peer-reviewed yet
• High Level Abstractions:
• (microgram,vaccine)

• challenge (Read more)
• The effort by Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has infected more than 10 million people worldwide and killed at least 511,851, according to data compiled by Johns Hopkins University
• High Level Abstractions:
• (covid-19,vaccine)
• Inferred entity relationships (2)

  (covid-19,vaccine,wuhan) [inferred]

  (covid-19,vaccine,zaks) [inferred]

• challenge (Read more)
• Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.
  The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv
• High Level Abstractions:
• (antibodies,vaccine)
• Inferred entity relationships (1)

  (antibodies,vaccine,zaks) [inferred]

• challenge (Read more)
• The effort by Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has infected more than 10 million people worldwide and killed at least 511,851, according to data compiled by Johns Hopkins University.
• High Level Abstractions:
• (vaccine,worldwide)
• (johns_hopkins_university,vaccine)

• challenge (Read more)
• The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv
• High Level Abstractions:
• (vaccine,virus)

• challenge (Read more)
• The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv.
• High Level Abstractions:
• (medrxiv,vaccine)

• WIP (Read more)
• Pfizer shares jumped after it released positive results from its closely watched early-stage human trial on a coronavirus vaccine.
  The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.
• High Level Abstractions:
• (microgram,vaccine)

• WIP (Read more)
• Scientists conducting larger vaccine studies later this year hope to answer lingering questions about Covid-19 antibodies.
  Pfizer said it expects to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021
• High Level Abstractions:
• (antibodies,vaccine)
• (covid-19,vaccine)
• Inferred entity relationships (3)

  (covid-19,vaccine,wuhan) [inferred]

  (antibodies,vaccine,zaks) [inferred]

  (covid-19,vaccine,zaks) [inferred]

• WIP (Read more)
• Developing, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take years, global health experts say.
  Dr. Anthony Fauci, the nation's leading infectious disease expert, has said he is "cautiously optimistic" scientists can find a safe and effective vaccine by early 2021.
• High Level Abstractions:
• (scientists,vaccine)

• WIP (Read more)
• "We are dedicated to develop potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency."
  The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany.
  The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany.
  Thomas Lohnes | Getty Images
  The U.S.-based pharmaceutical giant has been working alongside German drugmaker BioNTech
• High Level Abstractions:
• (health,vaccine)
• (global,vaccine)

• WIP (Read more)
• Developing, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take years, global health experts say.
  Dr. Anthony Fauci, the nation's leading infectious disease expert, has said he is "cautiously optimistic" scientists can find a safe and effective vaccine by early 2021
• High Level Abstractions:
• (health,vaccine)
• (global,vaccine)
• (experts,vaccine)
• Inferred entity relationships (3)

  (experts,vaccine,zaks) [inferred]

  (experts,vaccine,white_house) [inferred]

  (experts,vaccine,vaccines) [inferred]

Target rule match count: 17.0 Challenge: 0.24 Momentum: 0.00 WIP: 0.26